NCT00989950

Brief Summary

Methylphenidate may improve sleep in children with ADHD. By leaving Daytrana (methylphenidate) patch for a longer time then 9 hours, many children report short sleep latencies and better quality of sleep.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2009

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 6, 2009

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2009

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2011

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

June 14, 2012

Completed
Last Updated

July 19, 2012

Status Verified

July 1, 2012

Enrollment Period

1.2 years

First QC Date

September 30, 2009

Results QC Date

March 12, 2012

Last Update Submit

July 16, 2012

Conditions

Keywords

daytranasleep latencyadhd rating scalesADHD

Outcome Measures

Primary Outcomes (1)

  • Sleep Latency

    Measure by daily subject sleep diary

    9 weeks

Study Arms (4)

Daytrana 9 hr wear

EXPERIMENTAL
Drug: Daytrana

Daytrana 10 hr wear

EXPERIMENTAL
Drug: Daytrana

Daytrana 11 hr wear

EXPERIMENTAL
Drug: Daytrana

Daytrana 12 hr wear

EXPERIMENTAL
Drug: Daytrana

Interventions

Daytrana patch 10-30 mg administered once daily for 9hr

Also known as: methylphenidate transdermal system
Daytrana 9 hr wear

Eligibility Criteria

Age6 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • ADHD without significant comorbidity

You may not qualify if:

  • Cardiac disorder
  • Hypertension
  • Thyroid disease
  • Glaucoma
  • History of sudden death, motor tics and/or Tourette's syndrome
  • Hypersensitivity to methylphenidate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pediatric Neurology of the Ozarks

Springfield, Missouri, 65807, United States

Location

Related Publications (1)

  • Ashkenasi A. Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder. Pediatr Neurol. 2011 Dec;45(6):381-6. doi: 10.1016/j.pediatrneurol.2011.09.003.

MeSH Terms

Conditions

Attention Deficit Disorder with HyperactivitySleep Initiation and Maintenance Disorders

Interventions

Methylphenidate

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental DisordersSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Intervention Hierarchy (Ancestors)

PhenylacetatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Limitations and Caveats

Small sample size, did not permit an examination of more specific differences among patch wear time conditions. Small sample size resulted in weaker randomization to patch wear time sequences that was not completely balanced in baseline covariates.

Results Point of Contact

Title
Arie Ashkenasi, MD
Organization
CoxHealth

Study Officials

  • arie ashkenasi

    pediatric neurology of the ozarks

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Staff Neurologist

Study Record Dates

First Submitted

September 30, 2009

First Posted

October 6, 2009

Study Start

December 1, 2009

Primary Completion

February 1, 2011

Study Completion

February 1, 2011

Last Updated

July 19, 2012

Results First Posted

June 14, 2012

Record last verified: 2012-07

Locations